NuVasive (NASDAQ:NUVA) : The consensus on NuVasive (NASDAQ:NUVA) based on 15 analyst recommendation on the company stock is 1.4, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 12 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
NuVasive (NASDAQ:NUVA) : The consensus price target for NuVasive (NASDAQ:NUVA) is $60.55 for the short term with a standard deviation of $3.75. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $68, however, the pessimist price target for the company is $56.
For the current week, the company shares have a recommendation consensus of Buy.
NuVasive (NASDAQ:NUVA): stock turned positive on Tuesday. Though the stock opened at $57.8, the bulls momentum made the stock top out at $59.2 level for the day. The stock recorded a low of $57.79 and closed the trading day at $58.77, in the green by 1.70%. The total traded volume for the day was 764,079. The stock had closed at $57.79 in the previous days trading.
In an insider trading activity, Hannon Jason, officer (EVP, International) of Nuvasive Inc, unloaded 14,534 shares at an average price of $57.92 on June 15, 2016. The total amount of the transaction was worth $841,809, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Nuvasive, Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems, including NVM5 and NVJJB, Intra-Operative Monitoring (IOM) services and support; MaXcess, which is an integrated split-blade retractor system, and a variety of implants and biologics.